Table 1. Correlations between EIF2S2 expressions and clinicopathological characteristics.
| Characteristics | Low expression of EIF2S2 | High expression of EIF2S2 | P1 |
|---|---|---|---|
| n | 187 | 187 | |
| T stage, n (%) | 0.002* | ||
| T1 | 109 (29.4) | 74 (19.9) | |
| T2 | 37 (10.0) | 58 (15.6) | |
| T3 | 34 (9.2) | 46 (12.4) | |
| T4 | 4 (1.1) | 9 (2.4) | |
| N stage, n (%) | 0.622 | ||
| N0 | 126 (48.8) | 128 (49.6) | |
| N1 | 1 (0.4) | 3 (1.2) | |
| M stage, n (%) | 1.000 | ||
| M0 | 131 (48.2) | 137 (50.4) | |
| M1 | 2 (0.7) | 2 (0.7) | |
| Pathologic stage, n (%) | 0.002* | ||
| Stage I | 104 (29.7) | 69 (19.7) | |
| Stage II | 36 (10.3) | 51 (14.6) | |
| Stage III | 33 (9.4) | 52 (14.9) | |
| Stage IV | 3 (0.9) | 2 (0.6) | |
| Tumor status, n (%) | 0.083 | ||
| Tumor free | 111 (31.3) | 91 (25.6) | |
| With tumor | 69 (19.4) | 84 (23.7) | |
| Gender, n (%) | 0.122 | ||
| Female | 53 (14.2) | 68 (18.2) | |
| Male | 134 (35.8) | 119 (31.8) | |
| Race, n (%) | 0.670 | ||
| Asian | 76 (21.0) | 84 (23.2) | |
| Black or African American | 7 (1.9) | 10 (2.8) | |
| White | 94 (26.0) | 91 (25.1) | |
| Age, n (%) | 0.133 | ||
| ≤60 | 81 (21.7) | 96 (25.7) | |
| >60 | 106 (28.4) | 90 (24.1) | |
| Histologic grade2, n (%) | <0.001* | ||
| G1 | 36 (9.8) | 19 (5.1) | |
| G2 | 101 (27.4) | 77 (20.9) | |
| G3 | 45 (12.2) | 79 (21.4) | |
| G4 | 3 (0.8) | 9 (2.4) | |
| AFP (ng/mL), n (%) | <0.001* | ||
| ≤400 | 129 (46.1) | 86 (30.7) | |
| >400 | 18 (6.4) | 47 (16.8) | |
| Albumin (g/dL), n (%) | 0.421 | ||
| <3.5 | 40 (13.3) | 29 (9.7) | |
| ≥3.5 | 119 (39.7) | 112 (37.3) | |
| Child-Pugh grade, n (%) | 0.906 | ||
| A | 115 (47.7) | 104 (43.2) | |
| B | 10 (4.1) | 11 (4.6) | |
| C | 1 (0.4) | 0 (0) | |
| Vascular invasion, n (%) | 0.008* | ||
| No | 119 (37.4) | 89 (28.0) | |
| Yes | 45 (14.2) | 65 (20.4) | |
| Fibrosis Ishak score, n (%) | 0.635 | ||
| 0 | 45 (20.9) | 30 (14.0) | |
| 1/2 | 17 (7.9) | 14 (6.5) | |
| 3/4 | 13 (6.0) | 15 (7.0) | |
| 5/6 | 43 (20) | 38 (17.7) | |
| Residual tumor, n (%) | 0.025* | ||
| R0 | 171 (49.6) | 156 (45.2) | |
| R1 | 4 (1.2) | 13 (3.8) | |
| R2 | 1 (0.3) | 0 (0) | |
| Age, median [IQR] | 62 [53–69] | 60 [51–68] | 0.224 |
1, significance of EIF2S2 overexpression correlated with clinicopathological characteristics was calculated using chi-square test. *, P<0.05 is considered statistically significant. 2, Edmonson-Steiner histological grade. EIF2S2, eukaryotic translation initiation factor 2 subunit beta; AFP, α-fetoprotein.